Looking at the ranking of industrial enterprises of the Ministry of industry and information technology, what are the unexpected findings?

Source: two days before April 10, 2015, the Ministry of industry released the ranking of industrial enterprises in the pharmaceutical industry in 2014, which was based on three main indicators: total assets, main business income and total profits of pharmaceutical industry enterprises This year, there are 2048 pharmaceutical enterprises in the ranking (the ranking is based on the legal entity of industrial enterprises For the enterprises reported in the consolidated statements, the subordinate companies covered by the consolidation will not be listed separately), which is nearly 100 fewer than the 2146 enterprises last year In 2014, the ranking of the top 10 enterprises in the total assets of the pharmaceutical industry in terms of their main business income and total profits In fact, if you look at the business indicators of an enterprise, you will pay more attention to the main business income and total profits These two pieces are real money But judging by the wealth of the family, the total assets can still explain the problem However, a rich family does not mean a lot of money For example, Sichuan Kelun ranked 7th in terms of total assets, but ranked 28th and 24th in terms of total revenues and profits from its main businesses However, at least three indicators are all in the top 30 For example, North China Pharmaceutical ranked fifth in terms of total assets, sixth in terms of main business income, but 253 in terms of total profits In 2014, the ranking of total assets and total profits of the top 10 enterprises in the main business income of the pharmaceutical industry continued to look horizontally Among the top 10 enterprises in the main business income, Harbin Pharmaceutical Group, which ranked significantly behind in the total profits, ranked No 9 in the main business income and No 77 in the total profits In 2014, the ranking of total assets and main business income of top 10 enterprises in total profits of pharmaceutical industry From the top 10 of total profits, Pfizer ranked No 36 in total assets, slightly higher in main business income, and No 10 in the top, but the total profits ranked No 8 As for Fosun, its profit is significantly higher than that of its main business In this era of big price reduction of drugs, the added value of products is really important However, the most exaggerated thing is that Zhongheng, Wuzhou, ranks 10th in total profit, but its main business income ranks 73rd! Well, let's look at this year's situation horizontally, rather than across a few years In 2013 and 2012, the top 10 enterprises in total assets of the pharmaceutical industry in 2014 need to be mentioned here In the middle of 2012-2014, in 2013, Shanghai Pharmaceutical Group was reported in the consolidated statements, but the other two years were reported separately Therefore, Shanghai Pharmaceutical Group, ranking the second in total assets in 2013, did not enter the top 10 in 2012 and 2014 China Resources pharmaceutical and Tianjin Pharmaceutical Group have consolidated statements since 2013, so they have no ranking in 2012 Capital behavior, reorganization, M & A, spin off and so on are the main factors that affect the total assets In 2013 and 2012, Guangyao group ranked the first among the top 10 enterprises in the main business income of the pharmaceutical industry in 2014 (2011 was also the first year in a row, so it was the fourth year in a row), while Weigao group and Shiyao group all improved compared with the previous two years, while China Resources medical group, Harbin Pharmaceutical Group and Tianjin Pharmaceutical Group showed a downward trend In 2013 and 2012, the top 10 companies in total profits of pharmaceutical industry in 2014 were the first in two consecutive years since the consolidated statements of Cr pharma Pfizer has developed well in the past two years and its ranking has been rising It seems that its business in China has not been affected by the "patent cliff"! As for Wuzhou Zhongheng, it began to consolidate its financial statements in 2013, and its ranking increased significantly in 2014 When the Ministry of industry and information technology released the ranking of the express, it did not release the operation of the pharmaceutical industry in 2014, so the above three indicators only know the ranking, but do not know the specific value, so we look at it crosswise like this, which is also a bustling activity Of course, I believe that more people can see the doorway, so may as well leave a message for us to exchange!